Head-to-head evidence
HRX0701 vs Teneligliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
HRX0701
Developed by Jiangsu Hengrui Pharmaceuticals
NCT05415644 · Phase 1 · completed
This is a randomized, blinded, crossover comparison against the reference formulation, which is a sound design for its purpose, but it measures only drug levels in the blood rather than a diabetes outcome, and no results have been posted yet.
Teneligliptin · Tenelia
Developed by Mitsubishi Tanabe Pharma
NCT00974090 · Phase 3 · completed
The trial was properly randomized and double-blinded with a placebo control and a real hard clinical endpoint (HbA1c change), and enrollment (~96-98 per arm) was reasonable for a 12-week phase 3 add-on study. However, the posted results report only least-squares mean changes with standard errors and no explicit statistical significance test for the primary comparison, so while the numeric difference favors teneligliptin, whether it formally met its pre-specified endpoint cannot be confirmed from this record alone.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRX0701's landscape · Teneligliptin's landscape